Dr. John E. Ervin

Internal Medicine
Arthritis And Osteoporosis Associates P.C.
1010 Carondelet Dr Ste 426, 
Kansas City, MO 
Before you request
Arthritis And Osteoporosis Associates P.C.
1010 Carondelet Dr Ste 426, 
Kansas City, MO 

Overview

John Ervin is a primary care provider, practicing in Internal Medicine in Kansas City, Missouri.

His clinical expertise encompasses Parainfluenza, Osteoarthritis, Arthritis, and Ecthyma.

He is actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 16 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in MO

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Arthritis and Osteoporosis Associates P.C.
1010 Carondelet Dr Ste 426, Kansas City, MO 64114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2026
Intervention Type: Biological
Study Drug: RSVPreF3 OA investigational vaccine
Study Phase: Phase 3
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: June 24, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy Adults
A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy Adults
Enrollment Status: Completed
Publish Date: May 06, 2026
Intervention Type: Biological
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Drug
Study Drug: ABP-450
Study Phase: Phase 2
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, 22-Week and 30-Week Open-label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Pain for Subjects With Osteoarthritis of the Knee
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, 22-Week and 30-Week Open-label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Pain for Subjects With Osteoarthritis of the Knee
Enrollment Status: Completed
Publish Date: March 28, 2024
Intervention Type: Drug
Study Drug: X0002
Study Phase: Phase 3
Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure
Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure
Enrollment Status: Terminated
Publish Date: December 20, 2023
Intervention Type: Drug, Device
Study Drug: INO-4800
Study Phase: Phase 2/Phase 3
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
View 9 Less Clinical Trials

20 Total Publications

A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity.
A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity.
Journal: Human vaccines & immunotherapeutics
Published: October 14, 2024
Similar Doctors
Expertise in
13
conditions
Dr. Patrick M. Moriarty
Internal Medicine
Expertise in
13
conditions
Dr. Patrick M. Moriarty
Internal Medicine

Medical Pavilion

2000 Olathe Boulevard, 
Kansas City, KS 
 (6.7 miles away)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Moriarty is a primary care provider, practicing in Internal Medicine in Kansas City, Kansas. Dr. Moriarty is highly rated in 13 conditions, according to our data. His clinical expertise encompasses High Cholesterol, Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia (HoFH), and Defective Apolipoprotein B-100. Dr. Moriarty is currently accepting new patients.

Expertise in
43
conditions
Dr. Dushyant S. Dahiya
Internal Medicine
Expertise in
43
conditions
Dr. Dushyant S. Dahiya
Internal Medicine

Office

3901 Rainbow Blvd # 102, 
Kansas City, KS 
 (10.9 miles away)
913-588-6019
Languages Spoken:
English
See accepted insurances

Dushyant Dahiya is a primary care provider, practicing in Internal Medicine in Kansas City, Kansas. Dr. Dahiya is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Hereditary Pancreatitis, Gastrointestinal Bleeding, Acute Pancreatitis, Endoscopy, and Colonoscopy.

Expertise in
75
conditions
Dr. Vikas Agarwal
Internal Medicine
Expertise in
75
conditions
Dr. Vikas Agarwal
Internal Medicine
Before you request

Mosaic Life Care At St. Joseph-Internal Medicine Plaza 2

901 Heartland Rd Ste 3800, 
Saint Joseph, MO 
 (58.5 miles away)
816-671-4800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vikas Agarwal is a primary care provider, practicing in Internal Medicine in Saint Joseph, Missouri. Dr. Agarwal is highly rated in 75 conditions, according to our data. His clinical expertise encompasses Myositis, COVID-19, Takayasu Arteritis, Kidney Transplant, and Vertebroplasty. Dr. Agarwal is currently accepting new patients.

Frequently Asked Questions about Dr. John E. Ervin

How do I make an appointment with Dr. John E. Ervin?

You can book an appointment with Dr. John E. Ervin by calling their office at 816-943-1292. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John E. Ervin a top-rated expert for Parainfluenza?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John E. Ervin is classified as an Experienced expert for Parainfluenza, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John E. Ervin specialize in?

While Dr. John E. Ervin is a Internal Medicine, they have specific expertise in Parainfluenza, Osteoarthritis, and Arthritis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. John E. Ervin participate in research or clinical trials?

Yes. Dr. John E. Ervin has published 20 articles and abstracts on conditions like Parainfluenza. You can view a list of Dr. John E. Ervin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John E. Ervin accept my insurance?

Dr. John E. Ervin accepts most major insurance plans, including Blue Cross Blue Shield and Cigna. We recommend calling the office directly at 816-943-1292 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ervin's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile